<DOC>
	<DOC>NCT00437658</DOC>
	<brief_summary>This study is designed to see how a research compound (NBI-56418) works compared to DMPA-SC (also known as depo-provera) in women with endometriosis and to see how both may affect bone mineral density.</brief_summary>
	<brief_title>Safety and Efficacy Study of NBI-56418 in Endometriosis</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<criteria>Be female, aged 18 to 49 years, inclusive Have moderate to severe pelvic pain due to endometriosis Have been surgically (laparoscopy or laparotomy) diagnosed with endometriosis within the last 7 years and have recurrent or persistent endometriosis symptoms Have regular menstrual cycle (2333 day) Agree to use two forms of nonhormonal contraception during the study Are currently receiving GnRH agonist, GnRH antagonist, DMPASC or DMPAIM or have received any of these agents within the last 12 months Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month Have had surgery for endometriosis within the last month Are currently smoking more than 20 cigarettes per week Are using systemic steroids on a chronic or regular basis within 3 months Have uterine fibroids or other pelvic lesions â‰¥5 cm in diameter Have pelvic pain that is not caused by endometriosis Have unstable medical condition or chronic disease Have been pregnant within the last year and is currently breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>